natgillin/translations-raw huggingface dataset:
Bovilis BTV8, injektionsvæske, suspension til kvæg og får
Bovilis BTV8 suspension for injection for cattle and sheep
Bovin
Bovine
Bovin granulocyt-kolonistimulerende faktor (bG-CSF) er et naturligt forekommende protein, som produceres af mononukleare leukocytter, endotheliale celler og fibroblaster.
Bovine granulocyte colony stimulating factor is a naturally occurring protein produced by mononuclear leukocytes, endothelial cells and fibroblasts.
Bovin type 1-kollagen
Bovine Type I collagen
Bovin, kaprin, porcin, kanin, Equidae
Bovine, caprine, porcine, rabbit, Equidae
Bovin, koncentreret valle med et indhold af specifik immunglobulin-G mod E.coli F5 (K99) adhesin på  2.8 log10/ml.
Bovine concentrated lactoserum containing specific immunoglobulins G against E. coli F5 (K99) adhesin 2.8 log10/ml.
Bovin, koncentreret valle med et indhold af specifik immunglobulin-G mod E.coli F5 (K99) adhesin på 2.8* log10/ml. mikroagglutinationsmetode
Bovine concentrated lactoserum containing specific immunoglobulins G against E. coli F5 (K99) adhesin  2.8* log10/ml. microagglutination method
Bovin, koncentreret valle med et indhold af specifik immunglobulin-G mod E.coli F5 (K99) adhesin på 2.8* log10/ml. mikroagglutinationsmetode
Bovine concentrated lactoserum containing specific immunoglobulins G against E. coli F5 (K99) adhesin 2.8* log10/ml. microagglutination method
Bovin, koncentreret valle med et indhold af specifik immunglobulin-G mod E.coli F5 (K99) adhesinpå  2.8 log10/ml.
Bovine concentrated lactoserum containing specific immunoglobulin G against E. coli F5(K99) adhesin >2.8 log10/ml
Bovint gelatine Mannitol (E421) Aspartam (E951) Appelsinsmag
Bovine gelatin Mannitol (E421) Aspartame (E951) Orange flavour
Bovint kollagen.
Bovine collagen Carmellose
Bovint type I kollagen
Bovine Type I collagen
Bovis
EU/2/09/105/001
Bovis
ZULVAC
Bowens sygdom), Merkelcellecarcinom eller andre maligne eller præmaligne hudforandringer.
Bowen’s disease), Merkel cell carcinoma, or other malignant or premalignant skin lesions.
Bowens sygdom), Merkelcellecarcinom eller andre ondartede hudforandringer eller forstadier dertil.
Bowen’s disease), Merkel cell carcinoma or other malignant or premalignant skin problems.
bp < 0,001 sammenlignet med etanercept. cPatienter med Itch NRS ≥ 4 ved baseline: placebo N = 158, Taltz 80 mg Q4W N = 313, Taltz 80 mg Q2W N = 320, etanercept N = 312.
b p < 0.001 compared with etanercept c Patients with Itch NRS >= 4 at baseline: placebo N = 158, Taltz 80 mg Q4W N = 313, Taltz 80 mg Q2W N = 320, Etanercept N = 312
BP forbliver stabilt. dinutuximab alene i resten af behandlingsforløbet.
remains stable. alone for the remainder of the course.
Bradley, IL 60915 USA
Bradley, IL 60915 United States
Bradyfreni
Bradyphrenia
Bradyfreni
Very Rare
Bradykardi
Sinus arrhythmias Bradycardia
Bradykardi
Somnolence
Bradykardi
Ventricular
Bradykardi (bradykardi, nedsat hjertefrekvens, sinus bradykardi).
Bradycardia (Bradycardia, Heart rate decreased, Sinus bradycardia).
Bradykardi (unormalt lav hjertefrekvens),
Bradycardia (abnormally low heart rate),
Bradykardi <50 slag pr. minut
Bradycardia <50 beats per minute (bpm)
Bradykardi blev vurderet som et potentielt sikkerhedssignal, og 15 tilfælde blev gennemgået.
Bradycardia was evaluated as a potential safety signal and 15 cases were reviewed.
Bradykardi defineres som en hjertefrekvens under følgende grænser:
Bradycardia is defined below the following limits:
Bradykardi er ligeledes en kendt farmakologisk virkning fra systemisk beta-blokkerbehandling.
Bradycardia is also a well-known pharmacological effect from systemic beta blocker treatment.
Bradykardi som en infusionsrelateret bivirkning
Bradycardia as an infusion related adverse reaction
Bradykardi under følgende grænser:
Bradycardia below the following limits:
bradykardi vægtøgning/risiko for fedme
bradycardia weight increase/risk of obesity
Bradykardi*
Bradycardia
Bradykardi**, hjertestop**, hypotension**, vasodilatation**
Bradycardia**, cardiac arrest**, hypotension**, vasodilatation
Bradykardi, , hjertearytmi (sekundært til hypokalcæmi)
Bradycardia, cardiac arrhythmia (secondary to hypocalcaemia)
Bradykardi, kardiovaskulær sygdom
bradycardia, cardiovascular disorder
bradykardi, palpitationer
bradycardia, palpitations
bradykardi, takykardi
bradycardia, tachycardia
Bradykardi-fremkaldende calciumantagonister (diltiazem, verapamil, bepridil)
Bradycardia –inducing calcium-channel blockers (diltiazem, verapamil, bepridil)
Bradykardia (livstruende konsekvenser, akut intervention indiceret)
Bradycardiaa (life-threatening consequences, urgent intervention indicated)
Bradykardia (symptomatisk, kan være alvorlig og klinisk signifikant, medicinsk intervention indiceret)
Bradycardiaa (symptomatic, may be severe and medically significant, medical intervention indicated)
Bradykardic
Bradycardiac
Bradykardig (13%)
Bradycardiag (13%)
BRAF V600E (Primær)
BRAF V600E (Primary)
BRAF- mutation blev rapporteret hos 13% af studiepopulationen.
BRAF mutations were reported in 13% of the study population.
Brakial neuritis og Guillain-Barré syndrom er indberettet efter administration af en vaccine, der indeholder tetanus toxoid.
Brachial neuritis and Guillain-Barré Syndrome have been reported after administration of a tetanus toxoid containing vaccine
Brampton Road Hampden Park
Brampton Road, Hampden Park,
Brampton Road Hampden Park Eastbourne East Sussex BN22 9 AG
Brampton Road Hampden Park Eastbourne East Sussex BN22 9AG
Brampton Road Hampden Park Eastbourne East Sussex BN22 9AG
Brampton Road, Hampden Park, Eastbourne, East Sussex, BN22 9AG,
Brampton Road Hampden Park Eastbourne, East Sussex BN22 9AG
Brampton Road Hampden Park
Brampton Road, Hampden Park, Eastbourne East Sussex – BN22 9AG
Brampton Road, Hampden Park, Eastbourne, East Sussex - BN22 9AG
Brampton Road, Hampden Park, Eastbourne East Sussex, BN22 9AG
Brampton Road, Hampden Park, Eastbourne, East Sussex, BN22 9AG,
brandsår
Thermal burn;
Brasilien (Belém) 2008-2009
Brazil (Belém) 2008-2009
Brasilien (Recife) 2006-2008
Brazil (Recife) 2006-2008
Brat seponering af antiepileptika må ikke finde sted, da det kan føre til anfaldsrecidiv, hvilket kunne have alvorlige konsekvenser for både mor og barn.
No sudden discontinuation of anti-epileptic therapy should be undertaken as this may lead to breakthrough seizures which could have serious consequences for both mother and child.
Bravecto 112,5 mg (2-4,5 kg) Bravecto 250 mg (>4,5-10 kg) Bravecto 500 mg (>10-20 kg) Bravecto 1000 mg (>20-40 kg) Bravecto 1400 mg (>40-56 kg)
Bravecto 112.5 mg (2–4.5 kg) Bravecto 250 mg (>4.5 –10 kg) Bravecto 500 mg (>10 –20 kg) Bravecto 1000 mg (>20 –40 kg) Bravecto 1400 mg (>40 –56 kg)
Bravecto 112,5 mg spot-on, opløsning, til miniaturehunde (2 - 4,5 kg) Bravecto 250 mg spot-on, opløsning, til små hunde (> 4,5 - 10 kg) Bravecto 500 mg spot-on, opløsning, til mellemstore hunde (> 10 - 20 kg) Bravecto 1000 mg spot-on, opløsning, til store hunde (> 20 - 40 kg) Bravecto 1400 mg spot-on, opløsning, til meget store hunde (> 40 - 56 kg)
Bravecto 112.5 mg spot-on solution for very small dogs (2 – 4.5 kg) Bravecto 250 mg spot-on solution for small dogs (>4.5 – 10 kg) Bravecto 500 mg spot-on solution for medium-sized dogs (>10 – 20 kg) Bravecto 1000 mg spot-on solution for large dogs (>20 – 40 kg) Bravecto 1400 mg spot-on solution for very large dogs (>40 – 56 kg)
Bravecto 112,5 mg spot-on, opløsning, til miniaturehunde (2 - 4,5 kg) Bravecto 250 mg spot-on, opløsning, til små hunde (> 4,5 - 10 kg) Bravecto 500 mg spot-on, opløsning, til mellemstore hunde (> 10 - 20 kg) Bravecto 1000 mg spot-on, opløsning, til store hunde (> 20 - 40 kg) Bravecto 1400 mg spot-on, opløsning, til meget store hunde (> 40 - 56 kg) Fluralaner
Bravecto 112.5 mg spot-on solution for very small dogs (2 – 4.5 kg) Bravecto 250 mg spot-on solution for small dogs (>4.5 – 10 kg) Bravecto 500 mg spot-on solution for medium-sized dogs (>10 – 20 kg) Bravecto 1000 mg spot-on solution for large dogs (>20 – 40 kg) Bravecto 1400 mg spot-on solution for very large dogs (>40 – 56 kg) fluralaner
Bravecto 112,5 mg spot-on, opløsning, til miniaturehunde (2 - 4,5 kg) Bravecto 250 mg spot-on, opløsning, til små hunde (> 4,5 – 10 kg) Bravecto 500 mg spot-on, opløsning, til mellemstore hunde (> 10 - 20 kg) Bravecto 1000 mg spot-on, opløsning, til store hunde (> 20 - 40 kg) Bravecto 1400 mg spot-on, opløsning, til meget store hunde (> 40 - 56 kg) Fluralaner
Bravecto 112.5 mg spot-on solution for very small dogs (2-4.5 kg) Bravecto 250 mg spot-on solution for small dogs (>4.5 – 10 kg) Bravecto 500 mg spot-on solution for medium-sized dogs (>10 - 20 kg) Bravecto 1000 mg spot-on solution for large dogs (>20 – 40 kg) Bravecto 1400 mg spot-on solution for very large dogs (>40 – 56 kg) fluralaner
Bravecto 112,5 mg spot-on, opløsning, til små katte (1,2 - 2,8 kg) Bravecto 250 mg spot-on, opløsning, til mellemstore katte (> 2,8 - 6,25 kg) Bravecto 500 mg spot-on, opløsning, til store katte (> 6,25 - 12,5 kg)
Bravecto 112.5 mg spot-on solution for small cats (1.2 – 2.8 kg) Bravecto 250 mg spot-on solution for medium-sized cats (>2.8 – 6.25 kg) Bravecto 500 mg spot-on solution for large cats (>6.25 – 12.5 kg)
Bravecto 112,5 mg tyggetabletter til miniaturehunde (2-4,5 kg) Bravecto 250 mg tyggetabletter til små hunde (> 4,5-10 kg) Bravecto 500 mg tyggetabletter til mellemstore hunde (> 10-20 kg) Bravecto 1000 mg tyggetabletter til store hunde (> 20-40 kg) Bravecto 1400 mg tyggetabletter til meget store hunde (> 40-56 kg)
Bravecto 112.5 mg chewable tablets for very small dogs (2–4.5 kg) Bravecto 250 mg chewable tablets for small dogs (>4.5 –10 kg) Bravecto 500 mg chewable tablets for medium-sized dogs (>10–20 kg) Bravecto 1000 mg chewable tablets for large dogs (>20–40 kg) Bravecto 1400 mg chewable tablets for very large dogs (>40–56 kg)
Bravecto 112,5 mg tyggetabletter til miniaturehunde (2-4,5 kg) Bravecto 250 mg tyggetabletter til små hunde (>4,5-10 kg) Bravecto 500 mg tyggetabletter til mellemstore hunde (>10-20 kg) Bravecto 1000 mg tyggetabletter til store hunde (>20-40 kg) Bravecto 1400 mg tyggetabletter til ekstra store hunde (>40-56 kg)
Bravecto 112.5 mg chewable tablets for very small dogs (2–4.5 kg) Bravecto 250 mg chewable tablets for small dogs (>4.5 –10 kg) Bravecto 500 mg chewable tablets for medium-sized dogs (>10 –20 kg) Bravecto 1000 mg chewable tablets for large dogs (>20 –40 kg) Bravecto 1400 mg chewable tablets for very large dogs (>40–56 kg)
Bravecto 112,5 mg tyggetabletter til miniaturehunde (2-4,5 kg) Bravecto 250 mg tyggetabletter til små hunde (>4,5-10 kg) Bravecto 500 mg tyggetabletter til mellemstore hunde (>10-20 kg) Bravecto 1000 mg tyggetabletter til store hunde (>20-40 kg) Bravecto 1400 mg tyggetabletter til ekstra store hunde (>40-56 kg)
Bravecto 112.5 mg chewable tablets for very small dogs (2–4.5 kg) Bravecto 250 mg chewable tablets for small dogs (>4.5–10 kg) Bravecto 500 mg chewable tablets for medium-sized dogs (>10–20 kg) Bravecto 1000 mg chewable tablets for large dogs (>20–40 kg) Bravecto 1400 mg chewable tablets for very large dogs (>40–56 kg)
Bravecto er lægemiddel, der anvendes til behandling af angreb af lopper og flåter hos hunde og katte.
Bravecto is a veterinary medicine used to treat flea and tick infestations in dogs and cats.
Bravecto fås som spot-on opløsning i en pipette til hunde og katte og som tyggetabletter til hunde.
Bravecto is available as a spot-on solution in a pipette for use on dogs and cats and as chewable tablets for use in dogs.
Bravecto gives i henhold til nedenstående tabel (svarende til en dosis på 40 - 94 mg fluralaner/kg kropsvægt):
Bravecto should be administered in accordance with the following table (corresponding to a dose of 40 – 94 mg fluralaner/kg body weight):
Bravecto gives i henhold til nedenstående tabel (svarende til en dosis på 40 – 94 mg fluralaner/kg kropsvægt):
Bravecto should be administered in accordance with the following table (corresponding to a dose of 40 – 94 mg fluralaner/kg body weight):
Bravecto skal administreres i henhold til nedenstående tabel (svarende til en dosis på 25-56 mg fluralaner/kg kropsvægt inden for hver enkelt vægtgruppe):
Bravecto should be administered in accordance with the following table (corresponding to a dose of 25–56 mg fluralaner/kg bodyweight within one weight band):
Bravecto spot-on opløsning er meget brandfarlig og skal derfor holdes på afstand af varme, gnister, åben ild eller andre antændelseskilder.
Bravecto spot-on solution should be kept away from heat, sparks, open flames or other fire sources as it is highly flammable.
Bravecto spot-on opløsning og den våde hud af nyligt behandlede dyr kan virke let irriterende på hud og/eller øjne.
Bravecto spot-on solution and the wet skin of a recently treated animal may be slightly irritating to skin and/or eyes.
Bravecto tabletter gives ved hundens fodringstid som en tablet af passende styrke til hundens kropsvægt.
Bravecto tablets are given around the dog’s feeding time as a tablet of the appropriate strength for the dog’s bodyweight.
Bravecto tyggetabletter skal administreres i henhold til nedenstående tabel (svarende til en dosis på 25-56 mg fluralaner/kg kropsvægt inden for hver enkelt vægtgruppe):
Bravecto chewable tablets should be administered in accordance with the following table (corresponding to a dose of 25–56 mg fluralaner/kg bodyweight within one weight band):
Bravecto tyggetabletter til hunde
Bravecto chewable tablets for dogs
Bravecto udleveres kun efter recept.
Bravecto can only be obtained with a prescription.
Bray Business Park, Kilruddery County Wicklow
Bray Business Park Kilruddery
Bray Business Park, Kilruddery County Wicklow
Bray Business Park, Kilruddery, County Wicklow.
BREAK-MB var et ublindet fase II multicenterstudie med to kohorter, som var designet til vurdering af den intrakranielle respons på dabrafenib hos patienter med histologisk bekræftet BRAF- mutationspositivt (V600E eller V600K) melanom (stadium IV), som var metastaseret til hjernen.
BREAK-MB was a multicentre, open-label, two-cohort, Phase II study designed to evaluate the intracranial response of dabrafenib in subjects with histologically confirmed (Stage IV) BRAF- mutation positive (V600E or V600K) melanoma metastatic to the brain.
Bred ende
Thread
Bredskygget hat: for hoved, hals, næse og ører
Wide-brimmed hat: for head, neck, nose and ears.
bremse skader på brusk og knogler i leddene, som er forårsaget af sygdommen, forbedre din fysiske funktion og formåen i forhold til at varetage daglige gøremål.
low down the damage to the cartilage and bone of the joints caused by the disease, improve your physical function and performance of daily tasks.
bremse skader på brusk og knogler i leddene, som er forårsaget af sygdommen, forbedre dine fysiske funktion og formåen i forhold til at varetage daglige gøremål.
low down the damage to the cartilage and bone of the joints caused by the disease, improve your physical function and performance of daily tasks.
Brentford, Middlesex TW8 9GS Storbritannien
Brentford, Middlesex TW8 9GS United Kingdom
Bretaris Genuair 322 mikrogram inhalationspulver Aclidinium (aclidiniumbromid)
Bretaris Genuair 322 micrograms inhalation powder Aclidinium (aclidinium bromide)
Bretaris Genuair 322 µg inhalationspulver Aclidinium (aclidiniumbromid)
Bretaris Genuair 322 mcg inhalation powder Aclidinium (aclidinium bromide)
Bretaris Genuair anvendes til (regelmæssig) vedligeholdelsesbehandling.
Bretaris Genuair is used for maintenance (regular) treatment.
Bretaris Genuair anvendes til at lindre symptomerne ved kronisk obstruktiv lungesygdom (KOL) hos voksne.
Bretaris Genuair is used to relieve the symptoms of chronic obstructive pulmonary disease (COPD) in adults.
Bretaris Genuair er et hvidt eller næsten hvidt pulver.
Bretaris Genuair is a white or almost white powder.
Bretaris Genuair er et lægemiddel, der indeholder det aktive stof aclidiniumbromid.
Bretaris Genuair is a medicine that contains the active substance aclidinium bromide.
Bretaris Genuair er ikke beregnet til brug hos børn eller teenagere under 18 år.
Bretaris Genuair is not for use in children or adolescents below 18 years of age.
Bretaris Genuair er indiceret som bronkodilaterende vedligeholdelsesbehandling til lindring af symptomer hos voksne patienter med kronisk obstruktiv lungesygdom (KOL).
Bretaris Genuair is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Bretaris Genuair kan i mindre grad påvirke evnen til at føre motorkøretøj eller betjene maskiner.
Bretaris Genuair may have minor influence on the ability to drive and use machines.
Bretaris Genuair må ikke anvendes til personer, som er overfølsomme (allergiske) over for aclidiniumbromid, atropin, andre relaterede antikolinerge bronkodilatorer eller et af de øvrige indholdsstoffer.
Bretaris Genuair must not be used in people who are hypersensitive (allergic) to aclidinium bromide, atropine, other related anticholinergic bronchodilator medicines, or any of the other ingredients.
Bretaris Genuair reducerede signifikant hyperinflation under hvile (funktionel residualkapacitet [FRC]=0,197 l [95 % CI=0,321-0,072; p=0,002]; residualvolumen [RV]=0,238 l [95 % CI=0,396-0,079; p=0,004]) og forbedrede også inhalationskapaciteten (forbedrede dalværdien med 0,078 l; 95 % CI=0,01-0,145; p=0,025) og reducerede dyspnø i forbindelse med motion (Borg-skalaen) (med 0,63 Borg-enheder; 95
Bretaris Genuair statistically significantly reduced lung hyperinflation at rest (functional residual capacity [FRC]=0.197 L [95% CI=0.321, 0.072; p=0.002]; residual volume [RV]=0.238 L [95% CI=0.396, 0.079; p=0.004]) and also improved trough inspiratory capacity (by 0.078 L; 95% CI=0.01, 0.145; p=0.025) and reduced dyspnoea during exercise (Borg scale) (by 0.63 Borg units; 95% CI=1.11, 0.14; p=0.012).
Bretaris Genuair skal ikke anvendes ved astma; kliniske forsøg med aclidiniumbromid ved astma er ikke blevet udført.
Bretaris Genuair should not be used in asthma; clinical trials of aclidinium bromide in asthma have not been conducted.
Bretaris Genuair var mere effektivt end placebo til at forbedre lungefunktionen hos patienter med KOL.
Bretaris Genuair was more effective than placebo at improving how well the lungs work in patients with COPD.
BREV
POUCH
Brev
Sachet
Brev (alu)
Sachet (alu)
Brev (alu/PET/PE)
sachet (alu/PET/PE)
BREV (indeholder 1 depotplaster)
SACHET (Contains 1 transdermal patch)
Brev (LDPE/alu/PET)
sachet (LDPE/alu/PET)
Brev (LDPE/papirlaminat)
sachet (LDPE/paper laminate)
brev (overtrukket papir/alu/LLDPE)
sachet (coated paper/alu/LLDPE)
Brev (papir/Al/PE)
Sachet (paper/Al/PE)
Brev (papir/LDPE/alu/ethylen methacrylsyre copolymer)
sachet (paper/LDPE/Alu/ethylene methacrylic acid copolymer)
Brev (papir/LDPE/alu/LDPE)
sachet (Paper/LDPE/alu/ LDPE)
brev (papir/LDPE/aluminium/ET copolymer PE/aluminium/ET copolymer/papir)
sachet (paper/LDPE/alu/ET copolymer PE/Alu/ET copolymer/paper)
brev (papir/PE/alu)
sachet (paper/PE/alu)
brev (papir/polyester/ alu/polyacrylonitril)
achet (paper/polyester/alu/ polyacrylonitrile)
brev (papir/polyester/ alu/polyacrylonitril)
sachet (paper/polyester/alu/ polyacrylonitrile)
Brev (penta- laminat)
Sachet (penta- laminate)
Brev (PET/alu/LLDPE)
sachet (PET/alu/LLDPE)
Brev (PET/alu/PE)
Sachet (PET/alu/PE)
brev (PET/OPA/alu/LDPE)
sachet (PET/OPA/alu/LDPE)
brev (PET/PE/alu/PE/PVDC)
sachet (PET/PE/alu/PE/PVDC)
brev (polyester/alu)
sachet (polyester/Alu)
BREV KARTON
SACHET CARTON
Brev LDPE /alu/PET)
sachet (LDPE/alu/PET)
brev med 1 kutanplaster og 1 tube rensegel (50 g).
1 sachet containing 1 cutaneous patch and 1 tube of cleansing gel (50 g).
Breve
Sachet
BREVE
SACHETS
breve (LDPE)
sachet (LDPE)
Breve af ethylenmethacrylsyre copolymer, polyester, polyethylen med lav densitet og aluminium folielaminat, med varmeforsegling.
Sachet of ethylene methacrylic acid copolymer, polyester, low density polyethylene and aluminium foil laminate, with a heat seal.
Breve med forskellig pakningsstørrelse kan kombineres for at opnå den korrekte dosis, f.eks.:
Sachets of different pack size can be combined to achieve the correct dose, e.g.:
breve, der hver især indeholder 1 kutanplaster, samt 1 tube rensegel (50 g).
2 sachets, each containing 1 cutaneous patch and 1 tube of cleansing gel (50 g).
Brevene bør ikke bruges igen, efter at de er åbnede.
Sachets should not be re-used once opened.
Brevene kan opbevares ved temperaturer under 25 °C i op til 24 timer efter anbrud.
The sachets can be stored below 25°C up to 24 hours after first opening.
Brevene må først åbnes umiddelbart før brug.
The sachets should only be opened immediately prior to use.
Brevene må ikke bruges igen, efter at have været åbnet.
Sachets should not be re-used once opened.
Brevet/brevene må først åbnes, når dosis skal tilberedes.
Sachets should only be opened at the time of dose preparation.
BREVETIKET-TEKST
SACHET LABEL TEXT
BRF113710 (BREAK-2) var et multicenterstudie med én arm, hvor der var inkluderet 92 patienter med metastatisk melanom (stadium IV) med bekræftet BRAF V600E- eller V600K-mutationspositivt melanom.
BRF113710 (BREAK-2) was a multicentre, single-arm study that enrolled 92 subjects with metastatic melanoma (Stage IV) with confirmed BRAF V600E or V600K mutation-positive melanoma.
Bridgend, CF31 3RT Storbritannien
Bridgend, CF31 3RT United Kingdom
Bridion er en klar og farveløs til svagt gul opløsning til indsprøjtning.
Bridion is a clear and colourless to slightly yellow solution for injection.
Bridion indeholder natrium
Bridion contains sodium
Bridion kan anvendes, hvis du ammer.
Bridion can be used during breast-feeding.
Bridion kan nedsætte effekten af hormonelle præventionsmidler – inklusive p-piller, vaginalring, implantat eller hormonspiral – fordi det reducerer mængden af hormonet progestogen, som du får.
Bridion can make hormonal contraceptives - including the ‘Pill’, vaginal ring, implants or a hormonal IntraUterine System (IUS) - less effective because it reduces how much you get of the progestogen hormone.
Bridion påvirker ikke evnen til at køre bil og arbejde med maskiner.
Bridion has no known influence on your ability to drive and use machines.
BRIGHTER var et 3- armet randomiseret, aktivt kontrolleret studie, der sammenlignede 0,5 mg ranibizumab, givet som monoterapi eller i kombination med supplerende laserbehandling, med laserbehandling alene.
BRIGHTER was a 3-arm randomised active-controlled study that compared 0.5 mg ranibizumab given as monotherapy or in combination with adjunctive laser photocoagulation to laser photocoagulation alone.
Brilique anbefales ikke til børn og teenagere under 18 år.
Brilique is not recommended for children and adolescents under 18 years.
Brilique indeholder ticagrelor, som tilhører den kemiske gruppe CPTP (cyklopentyltriazolpyrimidiner), som er en oral direkte virkende, selektiv og reversibelt bindende P2Y12-receptorantagonist, der hindrer ADP-medieret P2Y12-afhængig trombocytaktivering og - aggregation.
Brilique contains ticagrelor, a member of the chemical class cyclopentyltriazolopyrimidines (CPTP), which is an oral, direct acting, selective and reversibly binding P2Y12 receptor antagonist that prevents ADP-mediated P2Y12 dependent platelet activation and aggregation.
Brilique påvirker celler, der kaldes ”blodplader” eller ”trombocytter”.
Brilique affects cells called ‘platelets’ (also called thrombocytes).
Brilique påvirker ikke tests af lungefunktionen.
Brilique does not affect tests of pulmonary function.
Brilliant Blue (E133) Allura Red AC (E129) Titaniumdioxid (E171) Sunset yellow FCF (E110)
Brilliant Blue (E133) Allura Red AC (E129) Titanium dioxide (E171) Sunset Yellow FCF (E110)
Brilliant blue (E133) Gul jernoxid (E172) Titandioxid (E171) Gelatine
Yellow iron oxide (E172) Titanium dioxide (E171) Gelatin
Brilliant Blue FCF (E133)
Brilliant Blue FCF E133
Brilliant Blue FCF (E133) Gul jernoxid (E172)
Titanium dioxide (E171) Brilliant Blue FCF (E133) Yellow iron oxide (E172)
Brilliant blue FCF aluminum lake (E133) Indigocarmin aluminum lake (E132)
Brilliant blue FCF aluminum lake (E133) Indigo carmine aluminum lake (E132)
Brilliant Blue FCF – (E133) Ammoniumhydroxid (E527) 28%
Brilliant Blue FCF (E133) Ammonium hydroxide (E527) 28